Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib with chemotherapy in Asian patients with advanced solid tumors
NCT02341456Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of adavosertib in solid tumor (advanced stage) (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of Patients With Treatment-Emergent Adverse Events at 21 days, Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs at 21 days and 2 more. Started Jan 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02341456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341456.